There has been a great deal of discussion about the use of adjuvants to improve the immunogenicity of vaccines against the 2009 H1N1 pandemic influenza strain. What effect do these compounds have on the immune response? Adjuvants are compounds added to vaccines that stimulate the immune response. They are often ...

Hosts: Vincent Racaniello and Dick Despommier On episode #47 of the podcast "This Week in Virology", Vincent and Dick discuss influenza virus-like particle vaccines produced in insect and plant cells, rapid sharing of influenza research, and answer listener questions about cytomegalovirus, viral evolution and symbiosis and much more. [powerpress url="http://traffic.libsyn.com/twiv/TWiV047.mp3"] ...

The second RNA segment of the influenza virus genome encodes the PB1 protein - part of the viral RNA polymerase - and, in some strains, a second protein called PB1-F2. The latter protein is believed to be an important determinant of influenza virus virulence. The absence of a full-length PB1-F2 ...

Two different influenza vaccines will be available in the fall of 2009. One will be a trivalent preparation comprising seasonal influenza H3N2 and H1N1 strains, plus an influenza B virus strain. A monovalent vaccine will also be available against the 2009 pandemic H1N1 strain. Many readers of virology blog have ...

In temperate climates, influenza displays distinct seasonality: infections mainly occur from November through March in the northern hemisphere, and from May to September in the southern hemisphere. The results of experiments in guinea pigs have revealed that aerosol transmission of influenza virus is most efficient in cold and dry conditions, ...